"" Lurbinectedin has shown evidence of activity in recurrent Small Cell Lung Cancer, both as a single agent and when given in combination with doxorubicin, a chemotherapy drug "".
Small Cell Lung Cancer: Future Directions in Care .
Insights From: Charles Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center.
Published: Thursday, Jan 02, 2020 .
“It is great to finally see some new therapeutic options arriving for small cell lung cancer patients, who represent a major unmet medical need,” said Charles Rudin, MD, PhD, chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and principal investigator of the NCI Small Cell Lung Cancer Consortium.
“I have been following the emerging clinical trial data on lurbinectedin, which suggest appealing efficacy and a tolerable safety profile. I believe many treating physicians may welcome lurbinectedin, if approved, as a new standard of care option for their patients with recurrent small cell lung cancer” . ...
